Arch Biopartners Inc. logo

Arch Biopartners Inc. (ARCH)

Market Closed
3 Jun, 20:00
TSX-V TSX-V
CA$
0. 4750
-0.015
-3.06%
CA$
114.95M Market Cap
- P/E Ratio
- Div Yield
27,605 Volume
- Eps
CA$ 0.49
Previous Close
Add Transaction
Day Range
0.465 0.51
Year Range
0.39 1.95
Want to track ARCH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ARCH closed today lower at CA$0.47, a decrease of -3.06% from yesterday's close, completing a monthly increase of 6.74% or CA$0.03. Over the past 12 months, ARCH stock lost -61.07%.
ARCH is not paying dividends to its shareholders.
The last earnings report, released on Jun 02, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on TSX-V (CAD).

ARCH Chart

Arch Biopartners Inc. (ARCH) FAQ

What is the stock price today?

The current price is CA$0.4750.

On which exchange is it traded?

Arch Biopartners Inc. is listed on TSX-V.

What is its stock symbol?

The ticker symbol is ARCH.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 114.95M.

Has Arch Biopartners Inc. ever had a stock split?

No, there has never been a stock split.

Arch Biopartners Inc. Profile

Biotechnology Industry
Healthcare Sector
Richard Gabriel Muruve CEO
TSX-V Exchange
CA03938C1041 ISIN
CA Country
6 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Arch Biopartners Inc., is a distinguished entity within the biopharmaceutical sector, primarily focused on the development of therapeutic drugs aimed at mitigating inflammation and tackling acute organ injuries. Operating from Toronto, Canada, alongside its subsidiaries, the company is at the forefront of addressing some of the most challenging medical conditions through its innovative drug development programs. With a keen emphasis on progressing their lead drug candidate, LSALT Peptide, through Phase 2 clinical trials, Arch Biopartners Inc. is pioneering the treatment of dipeptidase-1 mediated organ inflammation, a critical mediator of organ distress in the lungs, liver, and kidneys.

Products and Services

  • LSALT Peptide

    - LSALT Peptide stands as the flagship drug candidate of Arch Biopartners Inc., currently in Phase 2 clinical trials. This innovative therapeutic is being developed to address organ inflammation, primarily targeting the lungs, liver, and kidneys, by inhibiting dipeptidase-1. The potential of LSALT Peptide to mitigate organ distress offers a promising avenue for treating conditions characterized by severe inflammation.

  • AB569

    - AB569 marks another pivotal development within the company’s portfolio, aimed at combating antibiotic-resistant bacterial infections. This novel therapy is not only positioned to offer new hope in treating stubborn bacterial infections but also has applications in wound treatment. The dual functionality of AB569 underscores Arch Biopartners Inc.’s commitment to addressing both infectious diseases and their complications through innovative therapeutic approaches.

  • Borg

    - Diverging from the company's primary focus on drug development, Borg represents a unique product engineered to interface between peptides and solid surfaces, particularly targeting metal corrosion. This technological innovation not only highlights the versatility of Arch Biopartners Inc.’s research and development endeavours but also opens up new possibilities in materials science, offering solutions to extend the lifespan and reliability of metal components in various industrial applications.

Contact Information

Address: 27 Street Clair Avenue East
Phone: 647-428-7031